Will BMJ Study Linking EU-First Innovations With More Safety Alerts Prompt Tougher UK Regs?
This article was originally published in Clinica
Executive Summary
Findings from a new study which link a much higher rate of safety alerts with innovative devices that are approved first in the EU before going through the US FDA has been picked up by UK Brexit supporters as evidence of Brussels’ failure to regulate devices.
You may also be interested in...
TCT 2016: Cardiologists Urge More Alignment Between EU And US Regs
More robust oversight of medical devices in the EU is coming, and some European cardiologists speaking at the Transcatheter Cardiovascular Therapeutics annual meeting in Washington, DC, said that is a good thing despite the device industry’s history of praising the EU system for supporting innovation. They also pushed for more harmonization between the EU and US systems. Watch a video report from an FDA Town Hall panel at TCT on the topic and read our report from the meeting.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.